See more : Bayer Aktiengesellschaft (BAYN.SG) Income Statement Analysis – Financial Results
Complete financial analysis of Futura Medical plc (FAMDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Futura Medical plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bloom Dekor Limited (BLOOM.BO) Income Statement Analysis – Financial Results
- Organogenesis Holdings Inc. (ORGO) Income Statement Analysis – Financial Results
- Geologica Resource Corp. (GRCM.CN) Income Statement Analysis – Financial Results
- Jiangsu Zhongnan Construction Group Co., Ltd. (000961.SZ) Income Statement Analysis – Financial Results
- Pinelawn Cemetery (PLWN) Income Statement Analysis – Financial Results
Futura Medical plc (FAMDF)
About Futura Medical plc
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.10M | 0.00 | 0.00 | 0.00 | 31.78K | 0.00 | 362.73K | 170.36K | 29.48K | 43.93K | 370.90K | 75.00K | 158.00K | 125.00K | 50.00K | 150.00K | 15.00K | 0.00 | 2.00K | 130.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.33M | 24.73K | 19.81K | 25.01K | 0.00 | 19.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.77M | -24.73K | -19.81K | -25.01K | 31.78K | -19.85K | 362.73K | 170.36K | 29.48K | 43.93K | 370.90K | 75.00K | 158.00K | 125.00K | 50.00K | 150.00K | 15.00K | 0.00 | 2.00K | 130.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 57.22% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.05M | 4.13M | 3.77M | 1.93M | 10.05M | 6.04M | 4.10M | 3.51M | 4.78M | 2.37M | 1.98M | 1.44M | 1.00K | 762.00K | 810.00K | 1.40M | 1.52M | 1.08M | 1.55M | 960.00K | 627.00K | 811.00K | 683.00K | 207.00K |
| General & Administrative | 6.69M | 2.74M | 2.09M | 1.00M | 1.14M | 1.23M | 1.12M | 1.21M | 1.37M | 1.21M | 926.12K | 1.10M | 2.19M | 632.00K | 721.00K | 910.00K | 1.12M | 935.00K | 721.00K | 711.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.69M | 2.74M | 2.09M | 1.00M | 1.14M | 1.23M | 1.12M | 1.21M | 1.37M | 1.21M | 926.12K | 1.10M | 2.19M | 632.00K | 721.00K | 910.00K | 1.12M | 935.00K | 721.00K | 711.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.82K | -4.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -47.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.74M | 6.87M | 5.87M | 2.93M | 11.20M | 7.27M | 5.22M | 4.72M | 6.15M | 3.57M | 2.90M | 2.53M | 2.26M | 1.46M | 1.58M | 2.32M | 2.63M | 2.11M | 2.36M | 1.70M | 1.51M | 1.30M | 1.34M | 392.00K |
| Cost & Expenses | 10.06M | 6.87M | 5.87M | 2.93M | 11.20M | 7.27M | 5.22M | 4.72M | 6.15M | 3.57M | 2.90M | 2.53M | 2.26M | 1.46M | 1.58M | 2.32M | 2.63M | 2.11M | 2.36M | 1.70M | 1.51M | 1.30M | 1.34M | 392.00K |
| Interest Income | 71.80K | 0.00 | 0.00 | 924.00 | 22.28K | 27.58K | 19.32K | 14.71K | 38.33K | 48.26K | 9.53K | 18.49K | 24.00K | 19.00K | 14.00K | 97.00K | 161.00K | 136.00K | 133.00K | 177.00K | 48.00K | 60.00K | 22.00K | 6.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 1.00K | 29.00K | 16.00K |
| Depreciation & Amortization | 130.27K | 24.73K | 19.81K | 25.01K | 20.70K | 19.85K | 13.43K | 6.25K | 6.96K | 4.53K | 3.78K | 2.18K | 4.00K | 8.00K | 11.00K | 16.00K | 15.00K | 11.00K | 13.00K | 16.00K | 13.00K | 14.00K | 9.00K | 1.00K |
| EBITDA | -6.83M | -6.85M | -5.85M | -2.90M | -11.14M | -7.25M | -4.84M | -4.55M | -6.11M | -3.52M | -2.53M | -2.45M | -2.09M | -1.33M | -1.52M | -2.16M | -2.61M | -1.96M | -2.34M | -1.57M | -1.45M | -1.22M | -1.31M | -385.00K |
| EBITDA Ratio | -220.37% | 0.00% | 0.00% | 0.00% | -35,065.34% | 0.00% | -1,335.03% | -2,669.51% | -20,728.20% | -8,018.17% | -681.52% | -3,271.66% | -1,310.76% | -1,047.20% | -3,002.00% | -1,374.67% | -16,320.00% | 0.00% | -110,500.00% | -1,060.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -6.96M | -6.87M | -5.87M | -2.93M | -11.16M | -7.27M | -4.86M | -4.55M | -6.12M | -3.53M | -2.53M | -2.46M | -2.10M | -1.34M | -1.53M | -2.18M | -2.62M | -2.11M | -2.36M | -1.58M | -1.51M | -1.30M | -1.34M | -392.00K |
| Operating Income Ratio | -224.57% | 0.00% | 0.00% | 0.00% | -35,130.49% | 0.00% | -1,338.73% | -2,673.17% | -20,751.81% | -8,028.47% | -682.54% | -3,274.57% | -1,328.48% | -1,068.80% | -3,052.00% | -1,450.00% | -17,493.33% | 0.00% | -117,800.00% | -1,212.31% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 71.80K | 0.00 | 0.00 | 924.00 | 22.28K | 27.58K | 19.32K | 14.71K | 38.33K | 48.26K | 9.53K | 18.49K | 24.21K | 19.00K | 14.00K | 97.00K | 161.00K | 136.00K | 134.00K | 177.00K | 47.00K | 59.00K | -7.00K | -10.00K |
| Income Before Tax | -6.89M | -6.87M | -5.87M | -2.93M | -11.14M | -7.24M | -4.84M | -4.54M | -6.08M | -3.48M | -2.52M | -2.44M | -2.08M | -1.32M | -1.51M | -2.08M | -2.46M | -1.97M | -2.22M | -1.40M | -1.46M | -1.24M | -1.35M | -402.00K |
| Income Before Tax Ratio | -222.25% | 0.00% | 0.00% | 0.00% | -35,060.37% | 0.00% | -1,333.41% | -2,664.54% | -20,621.79% | -7,918.62% | -679.97% | -3,249.92% | -1,313.29% | -1,053.60% | -3,024.00% | -1,385.33% | -16,420.00% | 0.00% | -111,150.00% | -1,076.15% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -379.07K | -1.02M | -908.60K | -519.09K | -2.22M | -1.36M | -936.34K | -842.25K | -997.04K | -480.69K | -313.68K | -260.79K | -260.00K | -226.00K | -119.00K | -143.00K | -209.00K | -196.00K | -287.00K | -170.00K | -101.00K | -152.00K | -100.00K | -30.00K |
| Net Income | -6.51M | -5.85M | -4.96M | -2.41M | -8.92M | -5.88M | -3.90M | -3.70M | -5.08M | -3.00M | -2.21M | -2.18M | -1.82M | -1.09M | -1.39M | -1.94M | -2.25M | -1.78M | -1.94M | -1.23M | -1.36M | -1.09M | -1.25M | -372.00K |
| Net Income Ratio | -210.03% | 0.00% | 0.00% | 0.00% | -28,067.50% | 0.00% | -1,075.27% | -2,170.15% | -17,239.25% | -6,824.38% | -595.40% | -2,902.20% | -1,148.73% | -872.80% | -2,786.00% | -1,290.00% | -15,026.67% | 0.00% | -96,800.00% | -945.38% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.02 | -0.02 | -0.01 | -0.04 | -0.04 | -0.03 | -0.04 | -0.05 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 | -0.03 | -0.04 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.01 | -0.04 | -0.04 | -0.03 | -0.04 | -0.05 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 | -0.03 | -0.04 | -0.01 |
| Weighted Avg Shares Out | 294.91M | 287.48M | 271.05M | 243.72M | 204.66M | 131.94M | 121.32M | 101.93M | 99.59M | 89.96M | 78.04M | 75.17M | 72.18M | 67.95M | 62.58M | 57.95M | 55.92M | 52.60M | 48.96M | 48.34M | 43.15M | 40.96M | 30.88M | 27.36M |
| Weighted Avg Shares Out (Dil) | 294.91M | 287.48M | 271.05M | 243.72M | 204.66M | 131.94M | 121.32M | 101.93M | 99.59M | 89.96M | 78.04M | 75.17M | 72.18M | 67.95M | 62.58M | 57.95M | 55.92M | 52.60M | 48.96M | 48.34M | 45.29M | 40.96M | 30.88M | 27.36M |
Futura Medical: Pieces of the jigsaw falling into place, says investment bank
The past year has seen the pieces of the puzzle fall neatly into place for UK-based Futura Medical PLC (AIM:FUM, OTC:FAMDF), according to boutique investment bank, Liberum. The company has successfully obtained US marketing authorisation and secured a US marketing...
Futura Medical targets profitability as it sees early commercial traction for ED gel
Futura Medical PLC said it expects to be in a break-even position next year as the commercial traction grows around its erectile dysfunction gel Eroxon. The product, which has regulatory sign-off in the US as the first over-the-counter product of its kind,...
Futura says Eroxon will be launched in Saudi in the fourth quarter after securing green light
Futura Medical PLC (AIM:FUM, OTC:FAMDF) said it has secured regulatory approval for its fast-acting gel-based erectile dysfunction treatment, MED3000, in Saudi Arabia. The product will be launched and marketed by Labatec Pharma as Eroxon in the fourth quarter.
Futura Medical announces chair succession after ‘landmark' Haleon tie-up
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has announced Jeff Needham as its new non-executive chair, succeeding from John Clarke who has stepped down. Clarke joined Futura in 2011 and, in a statement, the company described him as instrumental in driving the...
Futura shares surged following positive announcement on ED treatment
Futura Medical PLC (AIM:FUM, OTC:FAMDF) surged in Monday's early trades following a bullish announcement regarding its MED3000 topical, gel-based erectile dysfunction treatment. The group entered into a licensing agreement with world-leading consumer health company Haleon PLC (LSE:HLN, NYSE:HLN) for the...
Futura Medical reaches deal with Haleon to commercialise ED treatment in US
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has entered into a licensing agreement with world-leading consumer health company Haleon PLC (LSE:HLN, NYSE:HLN) for the exclusive US commercialisation rights to Futura's topical, gel-based erectile dysfunction treatment MED3000 AIM-listed Futura, whose sexual health-focused proprietary...
Futura Medical primed for the next stage in its journey, says broker
Futura Medical PLC (AIM:FUM, OTC:FAMDF) earlier this week caught the market a little off guard as it shared revenue guidance for the first time as sales of its breakthrough erectile dysfunction gel start to build. According to research conducted by UK brokerage...
Futura Medical says early sales of erectile dysfunction gel met expectations
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has reported an encouraging growth trajectory for its erectile dysfunction gel, Eroxon. In an update ahead of the company's annual general meeting, the firm announced that initial orders and market demand for the product had...
UK eyes space solar generation with new grants
Universities and companies developing space-based solar power are set to receive millions in government grants, as the UK bids to bolster energy security in creative new ways. Cambridge University and EDF Energy will be among those awarded by the government...
Futura Medical valuation upgraded by broker, which sees significant upside after FDA nod
Liberum has updated its target price for Futura Medical PLC (AIM:FUM, OTC:FAMDF) shares from 121p to 142p after the latter's announcement of US Food & Drug Administration approval for MED3000, a treatment for erectile dysfunction (ED), according to the corporate...
Source: https://incomestatements.info
Category: Stock Reports